<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00163293</url>
  </required_header>
  <id_info>
    <org_study_id>BY9010/CA-101</org_study_id>
    <secondary_id>2007-003736-34</secondary_id>
    <secondary_id>U1111-1189-7814</secondary_id>
    <nct_id>NCT00163293</nct_id>
  </id_info>
  <brief_title>Efficacy of Ciclesonide Inhaled Once Daily Versus Other Corticosteroids Used for Treatment of Mild Asthma in Children (4 to 11 Years) (BY9010/CA-101)</brief_title>
  <acronym>POPCICLE</acronym>
  <official_title>Effect of Low Dose Continuous Treatment With Ciclesonide Over One Year on the Time to First Exacerbation in Children With Mild Asthma Versus Intermittent Treatment for Exacerbations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the efficacy of ciclesonide with respect to reduction of
      the number of asthma exacerbations in children with mild persistent asthma. Treatment
      medication will be administered as follows: ciclesonide will be inhaled once daily, using one
      of the two dose levels versus placebo together with other corticosteroids used as
      intermittent treatment. The study duration consists of a baseline period (3 to 4 weeks) and a
      treatment period (12 months). The study will provide further data on safety and tolerability
      of ciclesonide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called ciclesonide. Ciclesonide is being tested to
      treat children who have mild asthma.

      The study enrolled 240 patients. Participants were randomly assigned (by chance, like
      flipping a coin) to one of the three treatment groups—which remained undisclosed to the
      patient and study doctor during the study (unless there was an urgent medical need):

        -  Ciclesonide 100 µg

        -  Ciclesonide 200 µg

        -  Placebo (dummy inactive inhalation) - this is a metered-dose inhaler that looks like the
           study drug but has no active ingredient.

      All participants were asked to take two puffs from a metered-dose inhaler once daily, in the
      evening, for up to 12 months.

      This multi-center trial was conducted in Canada, Hungary and South Africa. The overall time
      to participate in this study was 12 months preceded by a baseline washout period of 3 to 4
      weeks. Participants made multiple visits to the clinic including a safety follow-up visit
      within 30 days of the last treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2005</start_date>
  <completion_date type="Actual">April 1, 2010</completion_date>
  <primary_completion_date type="Actual">June 1, 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to First Asthma Exacerbation</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Time to first asthma exacerbation is defined as the time in days until the first asthma exacerbation, or to the end of treatment visit. In the absence of an exacerbation, an early treatment discontinuation is treated as a censored observation on the day following the last use of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exacerbations (Post-hoc Analysis of Annual Rates)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>A model-based analysis of asthma exacerbation was performed to adjust to important covariables. The distribution of the data suggested a Poisson regression modeling (zero inflated) strategy. After a variable selection process considering also variable-by-treatment interactions, the variables centre, age [years] and race were identified to be important beside treatment. The parameters centre and age [years] were allocated to zero-model part and the variables treatment and race to the Poisson model part. The estimates of the per-treatment rates are based on a negative-binomial distribution.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Growth Velocity as Assessed by Stadiometric Height Measurement</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Standing height measured in millimeters (mm) with a wall-mounted stadiometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Rate of Asthma Exacerbations Per Year</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Rate of asthma exacerbations per year is equal to total number of asthma exacerbations during treatment/time on treatment (year).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Exacerbations</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Duration of exacerbation was defined as the time in days when the criteria for an exacerbation were met to the time when peak flow measurements returned to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Exacerbations Per Participant</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The mean number of asthma exacerbations per participant is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Dropped-out Due to Asthma Exacerbation</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Forced Expiratory Volume in One Second (FEV1) (Absolute Value)</measure>
    <time_frame>Baseline and Months 1, 2, 4, 6, 8, 10 and 12</time_frame>
    <description>FEV1 is the maximal amount of air forcefully exhaled from the lungs in one second. Spirometry was used for assessment of FEV1. A positive change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Forced Expiratory Volume in One Second (FEV1) (Percent Predicted)</measure>
    <time_frame>Baseline and Months 1, 2, 4, 6, 8, 10 and 12</time_frame>
    <description>FEV1 is the maximal amount of air forcefully exhaled from the lungs in one second. Spirometry was used for assessment of FEV1. A positive change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning and Evening Peak Expiratory Flow (PEF) Measurements by Diary Entries</measure>
    <time_frame>Months 1, 2, 4, 6, 8, 10 and 12</time_frame>
    <description>PEF is the maximum speed of expiration. Spirometry was used for assessment of PEF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PEF by Diary Entries</measure>
    <time_frame>Baseline and Months 1, 2, 4, 6, 8, 10 and 12</time_frame>
    <description>PEF is the maximum speed of expiration. Spirometry was used for assessment of PEF. A positive change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Diurnal PEF Fluctuation</measure>
    <time_frame>Baseline and Months 1, 2, 4, 6, 8, 10 and 12</time_frame>
    <description>Diurnal PEF Fluctuation is equal to [(Higher PEF - Lower PEF)/0.5*(Higher PEF + Lower PEF)] * 100%. A positive change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Asthma Symptom Score by Diary Entries</measure>
    <time_frame>Months 1, 2, 4, 6, 8, 10 and 12</time_frame>
    <description>Total Asthma Score = daytime asthma score + night-time asthma score, where higher score indicates worsening of disease. Night-time asthma score is assessed on a 5 point scale where 0=No symptoms, slept through the night, 1=Slept well but some complaints in the morning, 2=Woke up once because of asthma (including early wakening), 3=Woke up several times because of asthma (including early wakening) and 4=Bad night, awake most of the night because of asthma. Day-time asthma score is assessed on a 5 point scale where 0= Very well, no symptoms, 1= One episode of wheezing, cough or breathlessness, 2= More than one episode of wheezing, cough or breathlessness without interfering with normal activities, 3= Wheezing, cough or shortness of breath most of the day which interfered to some extent with normal activities and 4= Asthma very bad. Unable to carry out daily activities as usual.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Nights With Nocturnal Awakenings Due to Asthma Symptoms</measure>
    <time_frame>Months 1, 2, 4, 6, 8, 10 and 12</time_frame>
    <description>Nocturnal awakenings due to asthma symptoms were recorded in the participant's diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Medication Use Per Day</measure>
    <time_frame>Months 1, 2, 4, 6, 8, 10 and 12</time_frame>
    <description>Salbutamol (100 μg/puff) was used as rescue medication according to the individual needs of the participant. Each use was documented in the participant's diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Rescue Medication Free Days</measure>
    <time_frame>Months 1, 2, 4, 6, 8, 10 and 12</time_frame>
    <description>Days without use of rescue medication documented in the participant's diary were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Asthma Symptom Free Days</measure>
    <time_frame>Months 1, 2, 4, 6, 8, 10 and 12</time_frame>
    <description>Days without Asthma Symptom documented in the participant's diary were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessments as Per Paediatric Asthma Quality of Life Questionnaire, Standardized (PAQLQ[S])</measure>
    <time_frame>Months 2, 6 and 12</time_frame>
    <description>The PAQLQ(S) consists of 23 items divided into three domains: Activity limitations (items 1-3, 19, 22); Symptoms (items 4, 6, 8, 10, 12, 14, 16, 18, 20, 23) and Emotional function (items 5, 7, 9, 11, 13, 15, 17, 21). Participants were asked to answer each question using a seven-point scale (where &quot;1&quot; indicated maximum impairment and &quot;7&quot; indicated no impairment) and recall their experience during the previous week. Overall PAQLQ score is equal to the mean of all 23 items for a total possible score 1 (worst) to 7 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessments as Per Paediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ)</measure>
    <time_frame>Months 2, 6 and 12</time_frame>
    <description>The PACQLQ consists of 13 items divided into two domains: Activity limitations (items 2, 4, 6, 8) and Emotional function (items 1, 3, 5, 7, 9, 10, 11, 12, 13). Caregivers answered each question using a seven-point scale (whereby &quot;1&quot; indicated maximum impairment and &quot;7&quot; indicated no impairment) and recalled their experiences during the previous week. Overall PACQLQ score is equal to the mean of all 13 items for a total possible score of 1 (worst) to 7 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Vital Signs Findings</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Vital signs included body temperature, systolic and diastolic blood pressure and heart rate in beats per minute (bpm). The investigator determined if the result was clinically significant based on the following criteria: Systolic Blood Pressure &gt;130 mmHg or &lt;80 mmHg or a &gt;20 mmHg difference from Baseline; Diastolic Blood Pressure &gt; 85 mmHg; and Resting Heart Rate &gt;140 bpm or &lt;60 bpm or a &gt;30 bpm difference from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Physical Examination Findings</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>A thorough physical examination was performed consisting of examinations of the following body systems: (1) eyes; (2) ears, nose, throat; (3) lungs/thorax; (4) heart/cardiovascular system; (5) abdomen; (6) skin and mucosae; (7) nervous system; (8) lymph nodes; (9) musculo-skeletal system; (10) physical examinations other than body systems described in (1) to (9). The investigator determined if any of the findings were clinically significant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Laboratory Values</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Clinically significant laboratory values were hematology and chemistry tests determined by the investigator to be clinically significant based on the following criteria: Hemoglobin &lt;9.5 g/dL; Erythrocytes &lt;3.0 x 10^6/μL or &gt;6.5 x 10^6/μL; White Blood Count &lt;3000/mm^3 or &gt;20000/mm^3; serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), gamma-glutamyl transpeptidase (GGT), Total Bilirubin and Glucose &gt;2 times Upper limit of Normal Range (ULNR); Alkaline Phosphatase and Creatine Kinase &gt;3 times ULNR; Creatinine &gt;1.5 times ULN; Potassium &gt;5.0 mmol/L or &lt;3.0 mmol/L; and Sodium &gt;150 mmol/L or 130 mmol/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events and Serious Adverse Events</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in congenital anomaly/birth defect or any other important medical condition considered serious based on medical and scientific judgement.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ciclesonide 100 µg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ciclesonide 200 µg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclesonide</intervention_name>
    <description>Ciclesonide metered-dose inhaler</description>
    <arm_group_label>Ciclesonide 100 µg</arm_group_label>
    <arm_group_label>Ciclesonide 200 µg</arm_group_label>
    <other_name>Alvesco®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Ciclesonide placebo-matching metered-dose inhaler</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Outpatients

          -  Symptoms consistent with the diagnosis of asthma for at least 12 months

          -  Forced Expiratory Volume in one Second (FEV) at least 80% of predicted

          -  Participants who have a history of reversible airway obstruction

          -  Good health with the exception of asthma

        Main Exclusion Criteria:

          -  History of life-threatening asthma

          -  A hospitalization for asthma within the last 3 months, or more than two
             hospitalizations for asthma within the last year

          -  Concomitant severe diseases or diseases which are contraindications for the use of
             inhaled steroids

          -  Participants suffering from relevant lung diseases causing alternating impairment in
             lung function (e.g. chronic bronchitis or emphysema)

          -  Prematurely born children (&lt;36 weeks of gestation)

          -  Smokers

          -  Pregnancy (or intention to become pregnant during the course of the trial), breast
             feeding or lack of safe contraception by female of child-bearing potential
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca AstraZeneca</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Calgary</city>
        <zip>T2T5C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Fleurimont</city>
        <zip>J1H 5M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>London,ON</city>
        <zip>N6A1V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>London</city>
        <zip>N6C 4Y7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Winnipeg</city>
        <zip>R3A1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Kapstadt</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Hungary</country>
    <country>South Africa</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <results_first_submitted>December 1, 2010</results_first_submitted>
  <results_first_submitted_qc>December 1, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 22, 2010</results_first_posted>
  <disposition_first_submitted>July 1, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>July 1, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 7, 2010</disposition_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Ciclesonide</keyword>
  <keyword>Exacerbation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciclesonide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 30 investigative sites in Canada, Hungary and South Africa from 24 January 2005 to 25 June 2009.</recruitment_details>
      <pre_assignment_details>Children who experienced symptoms consistent with mild asthma for at least 12 months were enrolled in 1 of 3 treatment groups: once a day placebo, 100 µg or 200 µg ciclesonide.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ciclesonide 100 µg</title>
          <description>Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
        </group>
        <group group_id="P2">
          <title>Ciclesonide 200 µg</title>
          <description>Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Ciclesonide placebo-matching, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="76"/>
                <participants group_id="P3" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set included all randomized participants who received at least 1 dose of trial medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Ciclesonide 100 µg</title>
          <description>Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
        </group>
        <group group_id="B2">
          <title>Ciclesonide 200 µg</title>
          <description>Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Ciclesonide placebo-matching, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="79"/>
            <count group_id="B2" value="76"/>
            <count group_id="B3" value="84"/>
            <count group_id="B4" value="239"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.9" spread="2.06"/>
                    <measurement group_id="B2" value="7.7" spread="1.84"/>
                    <measurement group_id="B3" value="8.1" spread="2.19"/>
                    <measurement group_id="B4" value="7.9" spread="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <description>Weight data was only available for n=77, 76, 84 participants, respectively.</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.90" spread="9.701"/>
                    <measurement group_id="B2" value="30.01" spread="9.247"/>
                    <measurement group_id="B3" value="33.13" spread="11.640"/>
                    <measurement group_id="B4" value="31.08" spread="10.365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>BMI data was only available for n=77, 76, 84 participants, respectively.</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.30" spread="3.107"/>
                    <measurement group_id="B2" value="17.69" spread="2.977"/>
                    <measurement group_id="B3" value="18.68" spread="4.069"/>
                    <measurement group_id="B4" value="17.91" spread="3.478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Classification (Non-smoker)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to First Asthma Exacerbation</title>
        <description>Time to first asthma exacerbation is defined as the time in days until the first asthma exacerbation, or to the end of treatment visit. In the absence of an exacerbation, an early treatment discontinuation is treated as a censored observation on the day following the last use of study drug.</description>
        <time_frame>Up to 12 months</time_frame>
        <population>Intention to Treat (ITT) analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide 100 µg</title>
            <description>Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide 200 µg</title>
            <description>Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ciclesonide placebo-matching, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Asthma Exacerbation</title>
          <description>Time to first asthma exacerbation is defined as the time in days until the first asthma exacerbation, or to the end of treatment visit. In the absence of an exacerbation, an early treatment discontinuation is treated as a censored observation on the day following the last use of study drug.</description>
          <population>Intention to Treat (ITT) analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225.1" spread="14.73"/>
                    <measurement group_id="O2" value="249.5" spread="14.79"/>
                    <measurement group_id="O3" value="227.2" spread="15.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6625</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7303</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Exacerbations (Post-hoc Analysis of Annual Rates)</title>
        <description>A model-based analysis of asthma exacerbation was performed to adjust to important covariables. The distribution of the data suggested a Poisson regression modeling (zero inflated) strategy. After a variable selection process considering also variable-by-treatment interactions, the variables centre, age [years] and race were identified to be important beside treatment. The parameters centre and age [years] were allocated to zero-model part and the variables treatment and race to the Poisson model part. The estimates of the per-treatment rates are based on a negative-binomial distribution.</description>
        <time_frame>Up to 12 months</time_frame>
        <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide 100 µg</title>
            <description>Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide 200 µg</title>
            <description>Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ciclesonide placebo-matching, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Exacerbations (Post-hoc Analysis of Annual Rates)</title>
          <description>A model-based analysis of asthma exacerbation was performed to adjust to important covariables. The distribution of the data suggested a Poisson regression modeling (zero inflated) strategy. After a variable selection process considering also variable-by-treatment interactions, the variables centre, age [years] and race were identified to be important beside treatment. The parameters centre and age [years] were allocated to zero-model part and the variables treatment and race to the Poisson model part. The estimates of the per-treatment rates are based on a negative-binomial distribution.</description>
          <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome.</population>
          <units>number of events per year</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9343" spread="0.2909"/>
                    <measurement group_id="O2" value="0.8794" spread="0.2747"/>
                    <measurement group_id="O3" value="1.2621" spread="0.2768"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1291</p_value>
            <method>Wald Chi-square</method>
            <method_desc>zero inflated Poisson model: adjustment for centre and age [yrs] (zero model), treatment and race (Poisson model)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0145</p_value>
            <method>Wald Chi-square</method>
            <method_desc>zero inflated Poisson model: adjustment for centre and age [yrs] (zero model), treatment and race (Poisson model)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Growth Velocity as Assessed by Stadiometric Height Measurement</title>
        <description>Standing height measured in millimeters (mm) with a wall-mounted stadiometer.</description>
        <time_frame>Up to 12 months</time_frame>
        <population>Safety analysis set included all randomized participants who received at least 1 dose of trial medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide 100 µg</title>
            <description>Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide 200 µg</title>
            <description>Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ciclesonide placebo-matching, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Growth Velocity as Assessed by Stadiometric Height Measurement</title>
          <description>Standing height measured in millimeters (mm) with a wall-mounted stadiometer.</description>
          <population>Safety analysis set included all randomized participants who received at least 1 dose of trial medication.</population>
          <units>mm/year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.32" spread="25.81"/>
                    <measurement group_id="O2" value="64.60" spread="27.31"/>
                    <measurement group_id="O3" value="54.91" spread="21.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Rate of Asthma Exacerbations Per Year</title>
        <description>Rate of asthma exacerbations per year is equal to total number of asthma exacerbations during treatment/time on treatment (year).</description>
        <time_frame>Up to 12 months</time_frame>
        <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide 100 µg</title>
            <description>Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide 200 µg</title>
            <description>Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ciclesonide placebo-matching, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Rate of Asthma Exacerbations Per Year</title>
          <description>Rate of asthma exacerbations per year is equal to total number of asthma exacerbations during treatment/time on treatment (year).</description>
          <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome.</population>
          <units>number of exacerbations per year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" spread="1.366"/>
                    <measurement group_id="O2" value="0.85" spread="1.310"/>
                    <measurement group_id="O3" value="3.28" spread="19.874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4754</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6844</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Exacerbations</title>
        <description>Duration of exacerbation was defined as the time in days when the criteria for an exacerbation were met to the time when peak flow measurements returned to baseline.</description>
        <time_frame>Up to 12 months</time_frame>
        <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide 100 µg</title>
            <description>Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide 200 µg</title>
            <description>Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ciclesonide placebo-matching, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Exacerbations</title>
          <description>Duration of exacerbation was defined as the time in days when the criteria for an exacerbation were met to the time when peak flow measurements returned to baseline.</description>
          <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.17" spread="6.198"/>
                    <measurement group_id="O2" value="9.31" spread="7.650"/>
                    <measurement group_id="O3" value="7.92" spread="4.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Exacerbations Per Participant</title>
        <description>The mean number of asthma exacerbations per participant is reported.</description>
        <time_frame>Up to 12 months</time_frame>
        <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide 100 µg</title>
            <description>Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide 200 µg</title>
            <description>Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ciclesonide placebo-matching, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Exacerbations Per Participant</title>
          <description>The mean number of asthma exacerbations per participant is reported.</description>
          <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome.</population>
          <units>exacerbations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" spread="1.025"/>
                    <measurement group_id="O2" value="0.78" spread="1.028"/>
                    <measurement group_id="O3" value="0.95" spread="1.316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Dropped-out Due to Asthma Exacerbation</title>
        <time_frame>Up to 12 months</time_frame>
        <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide 100 µg</title>
            <description>Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide 200 µg</title>
            <description>Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ciclesonide placebo-matching, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Dropped-out Due to Asthma Exacerbation</title>
          <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="1.3"/>
                    <measurement group_id="O3" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Forced Expiratory Volume in One Second (FEV1) (Absolute Value)</title>
        <description>FEV1 is the maximal amount of air forcefully exhaled from the lungs in one second. Spirometry was used for assessment of FEV1. A positive change from Baseline indicates improvement.</description>
        <time_frame>Baseline and Months 1, 2, 4, 6, 8, 10 and 12</time_frame>
        <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide 100 µg</title>
            <description>Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide 200 µg</title>
            <description>Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ciclesonide placebo-matching, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Expiratory Volume in One Second (FEV1) (Absolute Value)</title>
          <description>FEV1 is the maximal amount of air forcefully exhaled from the lungs in one second. Spirometry was used for assessment of FEV1. A positive change from Baseline indicates improvement.</description>
          <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Month 1 (n=78, 76, 81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.019" spread="0.1715"/>
                    <measurement group_id="O2" value="0.018" spread="0.1639"/>
                    <measurement group_id="O3" value="0.012" spread="0.1627"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 2 (n=76, 73, 77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.024" spread="0.1416"/>
                    <measurement group_id="O2" value="0.060" spread="0.1582"/>
                    <measurement group_id="O3" value="0.005" spread="0.1416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 4 (n=68, 72, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.065" spread="0.1483"/>
                    <measurement group_id="O2" value="0.083" spread="0.1486"/>
                    <measurement group_id="O3" value="0.076" spread="0.1725"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 6 (n=67, 72, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.091" spread="0.1714"/>
                    <measurement group_id="O2" value="0.125" spread="0.1975"/>
                    <measurement group_id="O3" value="0.078" spread="0.1855"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 8 (n=66, 71, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.075" spread="0.2144"/>
                    <measurement group_id="O2" value="0.126" spread="0.2089"/>
                    <measurement group_id="O3" value="0.120" spread="0.1855"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 10 (n=66, 69, 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.143" spread="0.1458"/>
                    <measurement group_id="O2" value="0.168" spread="0.1910"/>
                    <measurement group_id="O3" value="0.146" spread="0.1609"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 12 (n=65, 69, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.161" spread="0.2022"/>
                    <measurement group_id="O2" value="0.185" spread="0.2024"/>
                    <measurement group_id="O3" value="0.178" spread="0.1593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Forced Expiratory Volume in One Second (FEV1) (Percent Predicted)</title>
        <description>FEV1 is the maximal amount of air forcefully exhaled from the lungs in one second. Spirometry was used for assessment of FEV1. A positive change from Baseline indicates improvement.</description>
        <time_frame>Baseline and Months 1, 2, 4, 6, 8, 10 and 12</time_frame>
        <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide 100 µg</title>
            <description>Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide 200 µg</title>
            <description>Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ciclesonide placebo-matching, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Expiratory Volume in One Second (FEV1) (Percent Predicted)</title>
          <description>FEV1 is the maximal amount of air forcefully exhaled from the lungs in one second. Spirometry was used for assessment of FEV1. A positive change from Baseline indicates improvement.</description>
          <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>percent predicted FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Month 1 (n=78, 76, 81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="10.96"/>
                    <measurement group_id="O2" value="0.6" spread="9.67"/>
                    <measurement group_id="O3" value="1.0" spread="9.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 2 (n=76, 73, 77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="8.50"/>
                    <measurement group_id="O2" value="3.4" spread="9.60"/>
                    <measurement group_id="O3" value="0.3" spread="8.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 4 (n=68, 72, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="8.69"/>
                    <measurement group_id="O2" value="4.6" spread="9.31"/>
                    <measurement group_id="O3" value="5.1" spread="9.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 6 (n=67, 72, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="10.00"/>
                    <measurement group_id="O2" value="7.2" spread="11.35"/>
                    <measurement group_id="O3" value="4.9" spread="10.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 8 (n=66, 71, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="12.44"/>
                    <measurement group_id="O2" value="6.5" spread="12.25"/>
                    <measurement group_id="O3" value="7.1" spread="10.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 10 (n=66, 69, 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="9.41"/>
                    <measurement group_id="O2" value="9.1" spread="10.48"/>
                    <measurement group_id="O3" value="8.7" spread="9.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 12 (n=65, 69, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="10.96"/>
                    <measurement group_id="O2" value="10.1" spread="11.29"/>
                    <measurement group_id="O3" value="10.4" spread="9.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning and Evening Peak Expiratory Flow (PEF) Measurements by Diary Entries</title>
        <description>PEF is the maximum speed of expiration. Spirometry was used for assessment of PEF.</description>
        <time_frame>Months 1, 2, 4, 6, 8, 10 and 12</time_frame>
        <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide 100 µg</title>
            <description>Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide 200 µg</title>
            <description>Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ciclesonide placebo-matching, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Morning and Evening Peak Expiratory Flow (PEF) Measurements by Diary Entries</title>
          <description>PEF is the maximum speed of expiration. Spirometry was used for assessment of PEF.</description>
          <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>liters/second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1, Evening PEF (n=78, 76, 80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235.72" spread="63.882"/>
                    <measurement group_id="O2" value="238.16" spread="52.565"/>
                    <measurement group_id="O3" value="241.89" spread="70.619"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1, Morning PEF (n=78, 76, 81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="232.09" spread="64.933"/>
                    <measurement group_id="O2" value="234.41" spread="52.908"/>
                    <measurement group_id="O3" value="233.81" spread="66.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2, Evening PEF (n=76, 71, 77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241.07" spread="58.604"/>
                    <measurement group_id="O2" value="241.16" spread="50.422"/>
                    <measurement group_id="O3" value="244.67" spread="67.846"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2, Morning PEF (n=76, 72, 77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="236.92" spread="61.243"/>
                    <measurement group_id="O2" value="236.42" spread="52.323"/>
                    <measurement group_id="O3" value="239.07" spread="70.132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4, Evening PEF (n=68, 72, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="249.75" spread="58.528"/>
                    <measurement group_id="O2" value="243.52" spread="49.076"/>
                    <measurement group_id="O3" value="245.91" spread="65.802"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4, Morning PEF (n=68, 71, 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="242.93" spread="56.658"/>
                    <measurement group_id="O2" value="241.91" spread="48.498"/>
                    <measurement group_id="O3" value="240.16" spread="65.211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, Evening PEF (n=67, 72, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251.88" spread="60.255"/>
                    <measurement group_id="O2" value="249.36" spread="59.294"/>
                    <measurement group_id="O3" value="246.44" spread="63.946"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, Morning PEF (n=67, 72, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246.44" spread="59.781"/>
                    <measurement group_id="O2" value="246.75" spread="60.020"/>
                    <measurement group_id="O3" value="238.81" spread="63.419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8, Evening PEF (n=66, 70, 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253.49" spread="59.666"/>
                    <measurement group_id="O2" value="250.92" spread="51.376"/>
                    <measurement group_id="O3" value="245.72" spread="61.399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8, Morning PEF (n=66, 71, 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247.24" spread="59.806"/>
                    <measurement group_id="O2" value="246.97" spread="51.592"/>
                    <measurement group_id="O3" value="239.73" spread="61.733"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10, Evening PEF (n=65, 70, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="254.21" spread="56.815"/>
                    <measurement group_id="O2" value="256.44" spread="56.469"/>
                    <measurement group_id="O3" value="251.69" spread="60.704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10, Morning PEF (n=66, 70, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247.94" spread="60.418"/>
                    <measurement group_id="O2" value="254.04" spread="56.719"/>
                    <measurement group_id="O3" value="246.23" spread="62.805"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, Evening PEF (n=68, 71, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255.97" spread="57.291"/>
                    <measurement group_id="O2" value="263.87" spread="58.469"/>
                    <measurement group_id="O3" value="261.88" spread="61.383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, Morning PEF (n=75, 73, 78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245.84" spread="59.834"/>
                    <measurement group_id="O2" value="258.62" spread="57.009"/>
                    <measurement group_id="O3" value="250.55" spread="63.204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PEF by Diary Entries</title>
        <description>PEF is the maximum speed of expiration. Spirometry was used for assessment of PEF. A positive change from Baseline indicates improvement.</description>
        <time_frame>Baseline and Months 1, 2, 4, 6, 8, 10 and 12</time_frame>
        <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide 100 µg</title>
            <description>Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide 200 µg</title>
            <description>Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ciclesonide placebo-matching, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PEF by Diary Entries</title>
          <description>PEF is the maximum speed of expiration. Spirometry was used for assessment of PEF. A positive change from Baseline indicates improvement.</description>
          <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>liters/second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Month 1, Evening PEF (n=78, 76, 80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.46" spread="17.952"/>
                    <measurement group_id="O2" value="8.54" spread="19.474"/>
                    <measurement group_id="O3" value="6.06" spread="39.183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 1, Morning PEF (n=78, 76, 81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.69" spread="21.268"/>
                    <measurement group_id="O2" value="10.82" spread="20.372"/>
                    <measurement group_id="O3" value="7.54" spread="25.697"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 2, Evening PEF (n=76, 71, 77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.66" spread="28.491"/>
                    <measurement group_id="O2" value="13.04" spread="20.890"/>
                    <measurement group_id="O3" value="10.83" spread="40.563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 2, Morning PEF (n=76, 72, 77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.12" spread="32.068"/>
                    <measurement group_id="O2" value="14.30" spread="22.649"/>
                    <measurement group_id="O3" value="14.29" spread="37.228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 4, Evening PEF (n=68, 72, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.41" spread="22.058"/>
                    <measurement group_id="O2" value="16.01" spread="21.547"/>
                    <measurement group_id="O3" value="13.62" spread="37.990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 4, Morning PEF (n=68, 71, 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.33" spread="26.603"/>
                    <measurement group_id="O2" value="18.24" spread="22.808"/>
                    <measurement group_id="O3" value="16.28" spread="34.841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 6, Evening PEF (n=67, 72, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.44" spread="28.236"/>
                    <measurement group_id="O2" value="21.86" spread="38.280"/>
                    <measurement group_id="O3" value="13.14" spread="33.321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 6, Morning PEF (n=67, 72, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.82" spread="30.613"/>
                    <measurement group_id="O2" value="24.68" spread="40.981"/>
                    <measurement group_id="O3" value="14.44" spread="29.950"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 8, Evening PEF (n=66, 70, 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.47" spread="27.430"/>
                    <measurement group_id="O2" value="21.38" spread="28.648"/>
                    <measurement group_id="O3" value="13.30" spread="37.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 8, Morning PEF (n=66, 71, 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.16" spread="32.530"/>
                    <measurement group_id="O2" value="23.76" spread="29.089"/>
                    <measurement group_id="O3" value="16.03" spread="34.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 10, Evening PEF (n=65, 70, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.68" spread="30.945"/>
                    <measurement group_id="O2" value="26.78" spread="34.255"/>
                    <measurement group_id="O3" value="18.04" spread="38.209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 10, Morning PEF (n=66, 70, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.86" spread="38.406"/>
                    <measurement group_id="O2" value="29.84" spread="36.390"/>
                    <measurement group_id="O3" value="21.25" spread="34.940"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 12, Evening PEF (n=68, 71, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.24" spread="28.811"/>
                    <measurement group_id="O2" value="33.35" spread="38.772"/>
                    <measurement group_id="O3" value="25.38" spread="43.284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 12, Morning PEF (n=75, 73, 78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.84" spread="32.932"/>
                    <measurement group_id="O2" value="34.31" spread="41.166"/>
                    <measurement group_id="O3" value="24.37" spread="39.312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Diurnal PEF Fluctuation</title>
        <description>Diurnal PEF Fluctuation is equal to [(Higher PEF – Lower PEF)/0.5*(Higher PEF + Lower PEF)] * 100%. A positive change from Baseline indicates improvement.</description>
        <time_frame>Baseline and Months 1, 2, 4, 6, 8, 10 and 12</time_frame>
        <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide 100 µg</title>
            <description>Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide 200 µg</title>
            <description>Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ciclesonide placebo-matching, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diurnal PEF Fluctuation</title>
          <description>Diurnal PEF Fluctuation is equal to [(Higher PEF – Lower PEF)/0.5*(Higher PEF + Lower PEF)] * 100%. A positive change from Baseline indicates improvement.</description>
          <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>percent fluctuation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Month 1 (n=78, 76, 80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="3.970"/>
                    <measurement group_id="O2" value="0.06" spread="3.772"/>
                    <measurement group_id="O3" value="0.00" spread="3.867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 2 (n=76, 71, 77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="5.009"/>
                    <measurement group_id="O2" value="-0.16" spread="4.131"/>
                    <measurement group_id="O3" value="0.15" spread="5.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 4 (n=68, 71, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" spread="5.251"/>
                    <measurement group_id="O2" value="-1.01" spread="3.784"/>
                    <measurement group_id="O3" value="-0.55" spread="4.421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 6 (n=67, 72, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.01" spread="4.351"/>
                    <measurement group_id="O2" value="-0.22" spread="5.860"/>
                    <measurement group_id="O3" value="-0.47" spread="4.280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 8 (n=66, 70, 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.12" spread="4.830"/>
                    <measurement group_id="O2" value="-1.21" spread="3.757"/>
                    <measurement group_id="O3" value="-1.11" spread="4.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 10 (n=64, 70, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.46" spread="5.221"/>
                    <measurement group_id="O2" value="-0.70" spread="4.319"/>
                    <measurement group_id="O3" value="-1.14" spread="4.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Month 12 (n=68, 70, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.81" spread="4.913"/>
                    <measurement group_id="O2" value="-0.62" spread="4.440"/>
                    <measurement group_id="O3" value="-1.26" spread="4.187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Asthma Symptom Score by Diary Entries</title>
        <description>Total Asthma Score = daytime asthma score + night-time asthma score, where higher score indicates worsening of disease. Night-time asthma score is assessed on a 5 point scale where 0=No symptoms, slept through the night, 1=Slept well but some complaints in the morning, 2=Woke up once because of asthma (including early wakening), 3=Woke up several times because of asthma (including early wakening) and 4=Bad night, awake most of the night because of asthma. Day-time asthma score is assessed on a 5 point scale where 0= Very well, no symptoms, 1= One episode of wheezing, cough or breathlessness, 2= More than one episode of wheezing, cough or breathlessness without interfering with normal activities, 3= Wheezing, cough or shortness of breath most of the day which interfered to some extent with normal activities and 4= Asthma very bad. Unable to carry out daily activities as usual.</description>
        <time_frame>Months 1, 2, 4, 6, 8, 10 and 12</time_frame>
        <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide 100 µg</title>
            <description>Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide 200 µg</title>
            <description>Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ciclesonide placebo-matching, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Asthma Symptom Score by Diary Entries</title>
          <description>Total Asthma Score = daytime asthma score + night-time asthma score, where higher score indicates worsening of disease. Night-time asthma score is assessed on a 5 point scale where 0=No symptoms, slept through the night, 1=Slept well but some complaints in the morning, 2=Woke up once because of asthma (including early wakening), 3=Woke up several times because of asthma (including early wakening) and 4=Bad night, awake most of the night because of asthma. Day-time asthma score is assessed on a 5 point scale where 0= Very well, no symptoms, 1= One episode of wheezing, cough or breathlessness, 2= More than one episode of wheezing, cough or breathlessness without interfering with normal activities, 3= Wheezing, cough or shortness of breath most of the day which interfered to some extent with normal activities and 4= Asthma very bad. Unable to carry out daily activities as usual.</description>
          <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 (n=77, 75, 79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.489"/>
                    <measurement group_id="O2" value="0.22" spread="0.329"/>
                    <measurement group_id="O3" value="0.32" spread="0.535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 (n=76, 70, 77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.424"/>
                    <measurement group_id="O2" value="0.14" spread="0.246"/>
                    <measurement group_id="O3" value="0.28" spread="0.484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4 (n=68, 72, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.342"/>
                    <measurement group_id="O2" value="0.12" spread="0.178"/>
                    <measurement group_id="O3" value="0.24" spread="0.359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=67, 72, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.289"/>
                    <measurement group_id="O2" value="0.17" spread="0.294"/>
                    <measurement group_id="O3" value="0.18" spread="0.289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8 (n=66, 69, 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.283"/>
                    <measurement group_id="O2" value="0.13" spread="0.243"/>
                    <measurement group_id="O3" value="0.23" spread="0.414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (n=64, 70, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.253"/>
                    <measurement group_id="O2" value="0.11" spread="0.227"/>
                    <measurement group_id="O3" value="0.24" spread="0.490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=68, 69, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.240"/>
                    <measurement group_id="O2" value="0.08" spread="0.129"/>
                    <measurement group_id="O3" value="0.15" spread="0.338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Nights With Nocturnal Awakenings Due to Asthma Symptoms</title>
        <description>Nocturnal awakenings due to asthma symptoms were recorded in the participant's diary.</description>
        <time_frame>Months 1, 2, 4, 6, 8, 10 and 12</time_frame>
        <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide 100 µg</title>
            <description>Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide 200 µg</title>
            <description>Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ciclesonide placebo-matching, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Nights With Nocturnal Awakenings Due to Asthma Symptoms</title>
          <description>Nocturnal awakenings due to asthma symptoms were recorded in the participant's diary.</description>
          <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>percentage of nights</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 (n=78, 75, 80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.40" spread="6.159"/>
                    <measurement group_id="O2" value="1.64" spread="4.256"/>
                    <measurement group_id="O3" value="1.85" spread="4.223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 (n=76, 73, 77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" spread="5.877"/>
                    <measurement group_id="O2" value="0.62" spread="2.364"/>
                    <measurement group_id="O3" value="1.73" spread="4.662"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4 (n=68, 72, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="4.017"/>
                    <measurement group_id="O2" value="0.86" spread="2.139"/>
                    <measurement group_id="O3" value="1.54" spread="4.106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=67, 72, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" spread="2.527"/>
                    <measurement group_id="O2" value="1.51" spread="3.288"/>
                    <measurement group_id="O3" value="1.26" spread="3.235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8 (n=66, 70, 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="4.129"/>
                    <measurement group_id="O2" value="1.05" spread="2.823"/>
                    <measurement group_id="O3" value="1.82" spread="5.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (n=66, 70, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" spread="7.106"/>
                    <measurement group_id="O2" value="0.59" spread="2.220"/>
                    <measurement group_id="O3" value="1.88" spread="5.468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=74, 73, 78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="1.554"/>
                    <measurement group_id="O2" value="1.84" spread="11.769"/>
                    <measurement group_id="O3" value="0.53" spread="1.853"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rescue Medication Use Per Day</title>
        <description>Salbutamol (100 μg/puff) was used as rescue medication according to the individual needs of the participant. Each use was documented in the participant’s diary.</description>
        <time_frame>Months 1, 2, 4, 6, 8, 10 and 12</time_frame>
        <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide 100 µg</title>
            <description>Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide 200 µg</title>
            <description>Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ciclesonide placebo-matching, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Rescue Medication Use Per Day</title>
          <description>Salbutamol (100 μg/puff) was used as rescue medication according to the individual needs of the participant. Each use was documented in the participant’s diary.</description>
          <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>puffs/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 (n=57, 51, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="1.345"/>
                    <measurement group_id="O2" value="0.83" spread="1.148"/>
                    <measurement group_id="O3" value="0.87" spread="0.910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 (n=53, 40, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" spread="1.296"/>
                    <measurement group_id="O2" value="0.53" spread="0.728"/>
                    <measurement group_id="O3" value="0.97" spread="1.298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4 (n=48, 47, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" spread="1.300"/>
                    <measurement group_id="O2" value="1.18" spread="1.595"/>
                    <measurement group_id="O3" value="1.27" spread="1.984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=45, 43, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="1.084"/>
                    <measurement group_id="O2" value="1.07" spread="1.329"/>
                    <measurement group_id="O3" value="0.92" spread="1.583"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8 (n=38, 42, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread="1.530"/>
                    <measurement group_id="O2" value="1.13" spread="1.950"/>
                    <measurement group_id="O3" value="0.97" spread="1.219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (n=38, 41, 39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="1.423"/>
                    <measurement group_id="O2" value="0.95" spread="1.243"/>
                    <measurement group_id="O3" value="0.83" spread="1.113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=36, 40, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="0.897"/>
                    <measurement group_id="O2" value="1.01" spread="1.360"/>
                    <measurement group_id="O3" value="0.75" spread="1.152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Rescue Medication Free Days</title>
        <description>Days without use of rescue medication documented in the participant’s diary were reported.</description>
        <time_frame>Months 1, 2, 4, 6, 8, 10 and 12</time_frame>
        <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide 100 µg</title>
            <description>Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide 200 µg</title>
            <description>Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ciclesonide placebo-matching, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Rescue Medication Free Days</title>
          <description>Days without use of rescue medication documented in the participant’s diary were reported.</description>
          <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 (n=55, 53, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.94" spread="44.405"/>
                    <measurement group_id="O2" value="47.34" spread="44.984"/>
                    <measurement group_id="O3" value="44.37" spread="45.367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 (n=52, 41, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.78" spread="46.442"/>
                    <measurement group_id="O2" value="54.46" spread="46.668"/>
                    <measurement group_id="O3" value="45.31" spread="47.761"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4 (n=49, 48, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.91" spread="48.274"/>
                    <measurement group_id="O2" value="46.51" spread="45.209"/>
                    <measurement group_id="O3" value="45.91" spread="46.328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=47, 44, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.63" spread="48.084"/>
                    <measurement group_id="O2" value="48.14" spread="45.321"/>
                    <measurement group_id="O3" value="49.42" spread="47.515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8 (n=39, 42, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.93" spread="45.170"/>
                    <measurement group_id="O2" value="50.50" spread="46.100"/>
                    <measurement group_id="O3" value="45.22" spread="45.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (n=40, 40, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.22" spread="47.901"/>
                    <measurement group_id="O2" value="49.78" spread="48.521"/>
                    <measurement group_id="O3" value="52.70" spread="46.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=35, 41, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.58" spread="47.785"/>
                    <measurement group_id="O2" value="53.63" spread="48.358"/>
                    <measurement group_id="O3" value="58.03" spread="46.264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Asthma Symptom Free Days</title>
        <description>Days without Asthma Symptom documented in the participant's diary were reported.</description>
        <time_frame>Months 1, 2, 4, 6, 8, 10 and 12</time_frame>
        <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide 100 µg</title>
            <description>Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide 200 µg</title>
            <description>Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ciclesonide placebo-matching, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Asthma Symptom Free Days</title>
          <description>Days without Asthma Symptom documented in the participant's diary were reported.</description>
          <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 (n=62, 60, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.32" spread="40.983"/>
                    <measurement group_id="O2" value="36.95" spread="42.207"/>
                    <measurement group_id="O3" value="35.00" spread="43.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2 (n=61, 50, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.47" spread="44.743"/>
                    <measurement group_id="O2" value="41.16" spread="44.738"/>
                    <measurement group_id="O3" value="33.56" spread="44.161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4 (n=54,55, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.57" spread="46.573"/>
                    <measurement group_id="O2" value="38.83" spread="44.042"/>
                    <measurement group_id="O3" value="35.78" spread="43.538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=53, 50, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.75" spread="46.474"/>
                    <measurement group_id="O2" value="39.87" spread="43.744"/>
                    <measurement group_id="O3" value="40.09" spread="45.274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8 (n=46, 46, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.86" spread="43.312"/>
                    <measurement group_id="O2" value="43.90" spread="45.377"/>
                    <measurement group_id="O3" value="40.03" spread="43.369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (n=43, 47, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.00" spread="46.575"/>
                    <measurement group_id="O2" value="41.65" spread="47.435"/>
                    <measurement group_id="O3" value="39.83" spread="44.332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=42, 44, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.20" spread="46.787"/>
                    <measurement group_id="O2" value="42.03" spread="47.093"/>
                    <measurement group_id="O3" value="44.61" spread="46.120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Assessments as Per Paediatric Asthma Quality of Life Questionnaire, Standardized (PAQLQ[S])</title>
        <description>The PAQLQ(S) consists of 23 items divided into three domains: Activity limitations (items 1-3, 19, 22); Symptoms (items 4, 6, 8, 10, 12, 14, 16, 18, 20, 23) and Emotional function (items 5, 7, 9, 11, 13, 15, 17, 21). Participants were asked to answer each question using a seven-point scale (where “1” indicated maximum impairment and “7” indicated no impairment) and recall their experience during the previous week. Overall PAQLQ score is equal to the mean of all 23 items for a total possible score 1 (worst) to 7 (best).</description>
        <time_frame>Months 2, 6 and 12</time_frame>
        <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide 100 µg</title>
            <description>Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide 200 µg</title>
            <description>Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ciclesonide placebo-matching, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Assessments as Per Paediatric Asthma Quality of Life Questionnaire, Standardized (PAQLQ[S])</title>
          <description>The PAQLQ(S) consists of 23 items divided into three domains: Activity limitations (items 1-3, 19, 22); Symptoms (items 4, 6, 8, 10, 12, 14, 16, 18, 20, 23) and Emotional function (items 5, 7, 9, 11, 13, 15, 17, 21). Participants were asked to answer each question using a seven-point scale (where “1” indicated maximum impairment and “7” indicated no impairment) and recall their experience during the previous week. Overall PAQLQ score is equal to the mean of all 23 items for a total possible score 1 (worst) to 7 (best).</description>
          <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 2 (n=70, 73, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.21" spread="0.979"/>
                    <measurement group_id="O2" value="6.27" spread="0.878"/>
                    <measurement group_id="O3" value="6.08" spread="1.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=65, 72, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.33" spread="0.874"/>
                    <measurement group_id="O2" value="6.26" spread="0.982"/>
                    <measurement group_id="O3" value="6.30" spread="0.933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=64, 69, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.42" spread="0.786"/>
                    <measurement group_id="O2" value="6.34" spread="0.946"/>
                    <measurement group_id="O3" value="6.36" spread="0.824"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Assessments as Per Paediatric Asthma Caregiver’s Quality of Life Questionnaire (PACQLQ)</title>
        <description>The PACQLQ consists of 13 items divided into two domains: Activity limitations (items 2, 4, 6, 8) and Emotional function (items 1, 3, 5, 7, 9, 10, 11, 12, 13). Caregivers answered each question using a seven-point scale (whereby “1” indicated maximum impairment and “7” indicated no impairment) and recalled their experiences during the previous week. Overall PACQLQ score is equal to the mean of all 13 items for a total possible score of 1 (worst) to 7 (best).</description>
        <time_frame>Months 2, 6 and 12</time_frame>
        <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide 100 µg</title>
            <description>Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide 200 µg</title>
            <description>Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ciclesonide placebo-matching, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Assessments as Per Paediatric Asthma Caregiver’s Quality of Life Questionnaire (PACQLQ)</title>
          <description>The PACQLQ consists of 13 items divided into two domains: Activity limitations (items 2, 4, 6, 8) and Emotional function (items 1, 3, 5, 7, 9, 10, 11, 12, 13). Caregivers answered each question using a seven-point scale (whereby “1” indicated maximum impairment and “7” indicated no impairment) and recalled their experiences during the previous week. Overall PACQLQ score is equal to the mean of all 13 items for a total possible score of 1 (worst) to 7 (best).</description>
          <population>ITT analysis set included all participants of the full analysis set who received at least one dose of study medication and had at least one post-baseline measurement of the primary efficacy outcome. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 2 (n=73, 73, 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.87" spread="1.196"/>
                    <measurement group_id="O2" value="6.16" spread="1.033"/>
                    <measurement group_id="O3" value="6.08" spread="1.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=67, 72, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.15" spread="1.005"/>
                    <measurement group_id="O2" value="6.16" spread="1.115"/>
                    <measurement group_id="O3" value="6.31" spread="0.927"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=66, 69, 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.32" spread="0.849"/>
                    <measurement group_id="O2" value="6.25" spread="0.712"/>
                    <measurement group_id="O3" value="6.31" spread="0.899"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Vital Signs Findings</title>
        <description>Vital signs included body temperature, systolic and diastolic blood pressure and heart rate in beats per minute (bpm). The investigator determined if the result was clinically significant based on the following criteria: Systolic Blood Pressure &gt;130 mmHg or &lt;80 mmHg or a &gt;20 mmHg difference from Baseline; Diastolic Blood Pressure &gt; 85 mmHg; and Resting Heart Rate &gt;140 bpm or &lt;60 bpm or a &gt;30 bpm difference from Baseline.</description>
        <time_frame>Up to 12 months</time_frame>
        <population>Safety analysis set included all randomized participants who received at least 1 dose of trial medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide 100 µg</title>
            <description>Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide 200 µg</title>
            <description>Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ciclesonide placebo-matching, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Vital Signs Findings</title>
          <description>Vital signs included body temperature, systolic and diastolic blood pressure and heart rate in beats per minute (bpm). The investigator determined if the result was clinically significant based on the following criteria: Systolic Blood Pressure &gt;130 mmHg or &lt;80 mmHg or a &gt;20 mmHg difference from Baseline; Diastolic Blood Pressure &gt; 85 mmHg; and Resting Heart Rate &gt;140 bpm or &lt;60 bpm or a &gt;30 bpm difference from Baseline.</description>
          <population>Safety analysis set included all randomized participants who received at least 1 dose of trial medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Physical Examination Findings</title>
        <description>A thorough physical examination was performed consisting of examinations of the following body systems: (1) eyes; (2) ears, nose, throat; (3) lungs/thorax; (4) heart/cardiovascular system; (5) abdomen; (6) skin and mucosae; (7) nervous system; (8) lymph nodes; (9) musculo-skeletal system; (10) physical examinations other than body systems described in (1) to (9). The investigator determined if any of the findings were clinically significant.</description>
        <time_frame>Up to 12 months</time_frame>
        <population>Safety analysis set included all randomized participants who received at least 1 dose of trial medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide 100 µg</title>
            <description>Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide 200 µg</title>
            <description>Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ciclesonide placebo-matching, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Physical Examination Findings</title>
          <description>A thorough physical examination was performed consisting of examinations of the following body systems: (1) eyes; (2) ears, nose, throat; (3) lungs/thorax; (4) heart/cardiovascular system; (5) abdomen; (6) skin and mucosae; (7) nervous system; (8) lymph nodes; (9) musculo-skeletal system; (10) physical examinations other than body systems described in (1) to (9). The investigator determined if any of the findings were clinically significant.</description>
          <population>Safety analysis set included all randomized participants who received at least 1 dose of trial medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Laboratory Values</title>
        <description>Clinically significant laboratory values were hematology and chemistry tests determined by the investigator to be clinically significant based on the following criteria: Hemoglobin &lt;9.5 g/dL; Erythrocytes &lt;3.0 x 10^6/μL or &gt;6.5 x 10^6/μL; White Blood Count &lt;3000/mm^3 or &gt;20000/mm^3; serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), gamma-glutamyl transpeptidase (GGT), Total Bilirubin and Glucose &gt;2 times Upper limit of Normal Range (ULNR); Alkaline Phosphatase and Creatine Kinase &gt;3 times ULNR; Creatinine &gt;1.5 times ULN; Potassium &gt;5.0 mmol/L or &lt;3.0 mmol/L; and Sodium &gt;150 mmol/L or 130 mmol/L.</description>
        <time_frame>Up to 12 months</time_frame>
        <population>Safety analysis set included all randomized participants who received at least 1 dose of trial medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide 100 µg</title>
            <description>Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide 200 µg</title>
            <description>Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ciclesonide placebo-matching, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Laboratory Values</title>
          <description>Clinically significant laboratory values were hematology and chemistry tests determined by the investigator to be clinically significant based on the following criteria: Hemoglobin &lt;9.5 g/dL; Erythrocytes &lt;3.0 x 10^6/μL or &gt;6.5 x 10^6/μL; White Blood Count &lt;3000/mm^3 or &gt;20000/mm^3; serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), gamma-glutamyl transpeptidase (GGT), Total Bilirubin and Glucose &gt;2 times Upper limit of Normal Range (ULNR); Alkaline Phosphatase and Creatine Kinase &gt;3 times ULNR; Creatinine &gt;1.5 times ULN; Potassium &gt;5.0 mmol/L or &lt;3.0 mmol/L; and Sodium &gt;150 mmol/L or 130 mmol/L.</description>
          <population>Safety analysis set included all randomized participants who received at least 1 dose of trial medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events and Serious Adverse Events</title>
        <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in congenital anomaly/birth defect or any other important medical condition considered serious based on medical and scientific judgement.</description>
        <time_frame>Up to 12 months</time_frame>
        <population>Safety analysis set included all randomized participants who received at least 1 dose of trial medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide 100 µg</title>
            <description>Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide 200 µg</title>
            <description>Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Ciclesonide placebo-matching, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events and Serious Adverse Events</title>
          <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in congenital anomaly/birth defect or any other important medical condition considered serious based on medical and scientific judgement.</description>
          <population>Safety analysis set included all randomized participants who received at least 1 dose of trial medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 12 months</time_frame>
      <desc>At each visit investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by participant or observed by investigator was recorded, irrespective of relation to treatment. All adverse events and serious adverse events were coded according to MedDRA versions 8.0, 8.1, 9.0 and 9.1.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ciclesonide 100 µg</title>
          <description>Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
        </group>
        <group group_id="E2">
          <title>Ciclesonide 200 µg</title>
          <description>Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Ciclesonide placebo-matching, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Myringoplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA v 9.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="76"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="20" subjects_affected="13" subjects_at_risk="79"/>
                <counts group_id="E2" events="18" subjects_affected="9" subjects_at_risk="76"/>
                <counts group_id="E3" events="30" subjects_affected="14" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="28" subjects_affected="18" subjects_at_risk="79"/>
                <counts group_id="E2" events="31" subjects_affected="19" subjects_at_risk="76"/>
                <counts group_id="E3" events="35" subjects_affected="16" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>non-serious</description>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="76"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <description>non-serious</description>
                <counts group_id="E1" events="60" subjects_affected="35" subjects_at_risk="79"/>
                <counts group_id="E2" events="64" subjects_affected="38" subjects_at_risk="76"/>
                <counts group_id="E3" events="82" subjects_affected="39" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E2" events="10" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>AstraZeneca Clinical Study Information Center</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>1-877-240-9479</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

